Navigation Links
Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
Date:9/13/2011

PRINCETON, N.J., Sept. 13, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that screening has begun in a Phase 2b, international study of PSI-7977 and PSI-938, two nucleotide analog polymerase inhibitors for the treatment of chronic hepatitis C (HCV). The QUANTUM trial will evaluate interferon-free regimens of PSI-7977 400mg QD and PSI-938 300mg QD with and without ribavirin over 12 or 24 weeks in patients with HCV who have not been treated previously. The trial will also evaluate the use of PSI-938 monotherapy.

"We are encouraged by the early efficacy and safety data being generated with our nucleotide analogs, PSI-7977 and PSI-938," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer.  "The QUANTUM trial is the first interferon-free, all-nucleotide study with an SVR endpoint. The ability to include all HCV genotypes was supported by data from the NUCLEAR study and the interferon free arms of the ELECTRON trial. Data from ELECTRON are expected later this year."

About the Phase 2b QUANTUM Trial This study is designed to enroll approximately 450 patients with chronic HCV of all viral genotypes who have not been treated previously. The primary endpoint of the trial will be sustained virological response (SVR24). Patients will be equally randomized across the following arms:

  • PSI-938 only
  • PSI-938 and PSI-7977
  • PSI-7977 and ribavirin
  • PSI-938, PSI-7977, and ribavirin

  • All arms will be study for both 12 and 24 weeks with a placebo control of 24 weeks.

  • Placebo for 24 weeks

  • HCV patients will be stratified by IL28B status and baseline HCV RNA to ensure balance across cohorts. Cirrhotic and non-cirrhotic patients will be enrolled in the study.

    Additional details on this and all ongoing Pharmasset sponsored trials can be found at

    SOURCE Pharmasset, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Pharmasset Announces Two-for-One Forward Stock Split
    2. Pharmasset to Present at Canaccord Genuity Growth Conference
    3. Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
    4. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
    5. Pharmasset to Present at Two Upcoming Investor Conferences
    6. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
    7. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
    8. Pharmasset to Webcast an Investor Event From the EASL Meeting
    9. Pharmasset to Present at Three Upcoming Investor Conferences
    10. Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
    11. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... , Jan. 23, 2015  MedScope ( www.medscope.org ), ... nominated for a 2015 Connected World magazine ... Response System (mPERS), that can be used anywhere, anytime. ... partner.  In nominating MedScope, Landon ...
    (Date:1/23/2015)... PHILADELPHIA , Jan. 23, 2015  Pete Rose, baseball,s all-time ... joint and arthritis pain reliever Myoflex, Ducere Pharma has announced. ... and we are excited to have him on board with ... . "He is a legendary player who is known across ...
    (Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
    Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
    ... Premier Purchasing Partners, LP, a leading healthcare purchasing network, has awarded a ... Management Division of Smith & Nephew, Inc., a subsidiary of Smith & ... hospitals and 64,000 other healthcare sites.  The three-year contract begins on ... , , ...
    ... announced today the launch of the EDUCARE (EDUcation for Cancer in African ... provide support to help combat the growing cancer epidemic in sub-Saharan Africa. ... The EDUCARE project ... a wider initiative to build regional training networks in cancer control and ...
    Cached Medicine Technology:Smith & Nephew Awarded Patient Cleansing and Skin Care Contract with Premier 2Smith & Nephew Awarded Patient Cleansing and Skin Care Contract with Premier 3Roche Announces Joint Initiative to Train Healthcare Workers in Africa's Fight Against Cancer 2Roche Announces Joint Initiative to Train Healthcare Workers in Africa's Fight Against Cancer 3Roche Announces Joint Initiative to Train Healthcare Workers in Africa's Fight Against Cancer 4
    (Date:1/22/2015)... EAGAN, Minn. (PRWEB) January 22, 2015 Blue ... discover those Minnesotans who exemplify what it means to “Live ... a chance for people to share their stories about how ... adversity or simply inspired others by living in the moment. ...
    (Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
    (Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
    (Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
    (Date:1/22/2015)... a new blog post explaining the importance of keeping a first ... an auto insurance policy . , Clients who driver safer ... vehicle insurance policies. The safety a vehicle offers from its driver ... this, drivers should always carry a first aid kit in their ...
    Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
    ... Amneal Pharmaceuticals is,pleased to announce that it ... USP in strengths of 5mg, 10mg, 25mg and ... an AA-Rated,therapeutically equivalent alternative to Urecholine(R) (a trademark ... breakthrough for Amneal, who is,one of the very ...
    ... Ill., Nov. 29 Abbott (NYSE:,ABT)announced today that ... Food and Drug Administration (FDA) recommended approval for ... V is a,next-generation drug eluting stent intended for ... The FDA advisory committee voted to recommend the ...
    ... (NYSE: BSX ) today welcomed the recommendation ... panel to approve with conditions the,PROMUS(TM) / XIENCE(TM) ... V stent systems are identical products, sold respectively,by ... stent,systems would be covered by the same FDA ...
    ... Nov. 29 As early detection and treatments,improve, ... Autism and,Asperger,s Syndrome are considering higher education., ... of an aging population,with autism, others have turned ... with Autism and Developmental Disabilities (AHEADD), to,enhance their ...
    ... 2007 Traditionally, clinicians have relied on information ... as the primary means of assessing patients symptoms ... arise if important symptoms go unreported during those ... new study by researchers at Memorial Sloan-Kettering Cancer ...
    ... Experts Address Smart Solutions to Keep Program,Accessible and Affordable, ... Medical Society hosted a panel discussion with local voters ... Medicare could,leave the program after scheduled pay cuts go ... people in the program to find a doctor. But ...
    Cached Medicine News:Health News:FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System 2Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 2Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 3Health News:Autism U: As College Application Deadlines Near, Growing Adult Autism Population Focuses on Higher Education 2Health News:Cancer patients may benefit from reporting symptoms online in real time 2Health News:Cancer patients may benefit from reporting symptoms online in real time 3Health News:Cancer patients may benefit from reporting symptoms online in real time 4Health News:AARP Pennsylvania Hosts Panel on Strengthening Medicare 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: